VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2021 | KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer

Combination therapy with the anti-HER2 antibody trastuzumab with pembrolizumab and chemotherapy is the current standard of care for patients with HER2-positive metastatic gastric or gastroesophageal junction cancer (G/GEJ). In this interview, Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the initial results from KEYNOTE-811 (NCT03615326), a Phase III study evaluating trastuzumab and chemotherapy with or without pembrolizumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter